芪苈强心胶囊联合沙库巴曲缬沙坦对慢性心力衰竭患者NT-proBNP水平及心功能的影响

Impact of Qili Qiangxin Capsules and Sacubitril Valsartan on NT-proBNP Level and Cardiac Function in Patients with Chronic Heart Failure

目的探讨芪苈强心胶囊联合沙库巴曲缬沙坦治慢性心力衰竭(CHF)患者的效果。方法将2021年1月至2023年1月我院收治的116例CHF患者随机分为对照组与观察组各58例。对照组给予沙库巴曲缬沙坦钠片治疗,观察组在对照组基础上采用芪苈强心胶囊治疗,两组均连续治疗12周。比较两组的临床疗效、NT-proBNP水平、心功能和不良反应。结果观察组治疗总有效率为91.38%,高于对照组的77.59%(P<0.05)。治疗后,观察组LVEF高于对照组,LVEDD、LVESD、NT-proBNP低于对照组(P<0.05)。两组不良反应发生率比较无统计学差异(P>0.05)。结论芪苈强心胶囊联合沙库巴曲缬沙坦治疗CHF患者的效果显著,可改善心功能指标,降低NT-proBNP水平,安全可靠,值得推广应用。

Objective To explore the effect of Qili Qiangxin capsule combined with sacubitril valsartan in the treatment of chronic heart failure(CHF).Methods 116 CHF patients admitted to our hospital from January 2021 to January 2023 were randomly divided into control group(58 cases)and observation group(58 cases).The control group was treated with sacubitril valsartan sodium tablets,while the observation group was treated with Qili Qiangxin capsules on the basis of the control group.Both groups were treated continuously for 12 weeks.The clinical efficacy,NT-proBNP levels,cardiac function and adverse reactions of the two groups were compared.Results The total effective rate of treatment in the observation group was 91.38%,higher than 77.59%in the control group(P<0.05).After treatment,the LVEF of the observation group was higher than that of the control group,and the LVEDD,LVESD and NT-proBNP were lower than those of the control group(P<0.05).No statistical difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Qili Qiangxin capsules combined with sacubitril valsartan has significant effect in the treatment of CHF patients,can improve the cardiac function indicators,and reduce the NT-proBNP level,which is safe,reliable and worthy of promotion and application.